The FDA has approved Alexion Pharmaceuticals' Soliris, or eculizumab, an injectible for adults positive for the anti-aquaporin-4 antibody, as the first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. Soliris is also approved for paroxysmal nocturnal hemoglobinuria and two other diseases.
FDA OKs eculizumab for neuromyelitis optica spectrum disorder
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.